Neuropsychotherapeutics

by Jeffrey M. Witkin (Editor)

Overview

Neuropsychotherapeutics, Volume 86, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field, with this updated edition including sections on Pharmacotherapy of psychiatric disorders, Allosteric mechanisms for neuropsychopharmacology, Lipid rafts, Rapid-acting antidepressants, mGlu2/3 receptor antagonists, Nitric oxide: antidepressant mechanisms and inflammation, Anxiety disorders, mGlu receptors and schizophrenia, mAChR ligands for schizophrenia and addiction, PDE10 inhibitors, Obsessive-compulsive disorder, Addiction disorders (including eating), Dopamine D1 PAMs as a New Mode for Treatment of Neuropsychiatric Disorders, and more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

Product Details

ISBN-13:	9780128166697
Publisher:	Elsevier Science & Technology Books
Publication date:	08/02/2019
Series:	Advances in Pharmacology , #86
Sold by:	Barnes & Noble
Format:	eBook
Pages:	320
File size:	14 MB
Note:	This product may take a few minutes to download.

About the Author

Jeffrey M. Witkin, Witkin Consulting Group, IN, USA

Table of Contents

1. GPCR drug discovery-moving beyond the orthosteric to the allosteric domainChristian C. Felder2. Lipid rafts in psychiatryNathan H. Wray and Mark M. Rasenick3. Rapid-acting antidepressantsJeffrey M. Witkin, Anna E. Martin, Lalit K. Golani, Nina Z. Xu and Jodi L. Smith4. mGlu2/3 receptor antagonistsShigeyuki Chaki5. Nitric oxide: Antidepressant mechanisms and inflammationMehdi Ghasemi6. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disordersLaura B. Teal, Robert W. Gould, Andrew S. Felts and Carrie K. Jones7. Medications development for food-based and drug use disordersFernando B. de Moura, Stephen J. Kohut and Jack Bergman8. Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic researchErik Z. Woody, Kurt Leroy Hoffman and Henry Szechtman9. Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disordersKjell A. Svensson, Junliang Hao and Robert F. Bruns

What People are Saying About This

From the Publisher

Provides the authority and expertise of leading contributors who discuss advances in pharmacology